Additional file 1 of Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study

Cheung, Ching-Lung; Sing, Chor-Wing; Lau, Wallis C. Y.; Li, Gloria H. Y.; Lip, Gregory Y. H.; Tan, Kathryn C. B.; Cheung, Bernard M. Y.; Chan, Esther W. Y.; Wong, Ian C. K.

doi:10.6084/m9.figshare.14313512.v1

12933_2021_1263_MOESM1_ESM.docx (89.47 kB)

Additional file 1 of Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population‐based cohort study

journal contribution

posted on 2021-03-26, 04:43 authored by Ching-Lung Cheung, Chor-Wing Sing, Wallis C. Y. Lau, Gloria H. Y. Li, Gregory Y. H. Lip, Kathryn C. B. Tan, Bernard M. Y. Cheung, Esther W. Y. Chan, Ian C. K. Wong

Additional file 1: Table S1. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes used in the study. Table S2. Subgroup analysis by age group. Table S3. Sensitivity analysis excluding patients with chronic kidney diseases. Table S4. Sensitivity analysis by excluding patients diagnosed with diabetes during the first 30 days of the follow-up period. Fig. S1. Cumulative incidence of diabetes in patients receiving anticoagulants (warfarin, apixaban, dabigatran, and rivaroxaban) after atrial fibrillation. Fig. S2. Cumulative incidence of diabetes in patients receiving anticoagulants (warfarin, apixaban/rivaroxaban, and dabigatran) after atrial fibrillation.